Ibrutinib is active both in treatment-naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients, including those with unmutated immunoglobulin heavy chain variable region (IGHV) genes and TP53 disruption.1-3 The acquisition of BTK or PLCg2 gene mutations conferring resistance, supports the existence of clonal evolution also under ibrutinib treat ment.4-8 Whilst it is well described that subclonal TP53 mutations undergo a positive clonal selection following chemoimmunotherapy (CIT),9-11 being the main driver of treatment failure, recent studies have suggested that this might not be the case under ibrutinib.
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia / Cafforio, L., Raponi, S., Cappelli, L.V., Ilari, C., Soscia, R., de Propris, M.S., Mariglia, P., Rigolin, G.M., Bardi, A., Peragine, N., Piciocchi, A., Arena, V., Mauro, F.R., Cuneo, A., Guarini, A., Foa, R., Del Giudice, I.. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 107:1(2022), pp. 334-337. [10.3324/haematol.2020.263715]
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia
Cafforio L.;Raponi S.;Cappelli L. V.;Ilari C.;Soscia R.;de Propris M. S.;Peragine N.;Mauro F. R.;Guarini A.;Foa R.;Del Giudice I.
2022
Abstract
Ibrutinib is active both in treatment-naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients, including those with unmutated immunoglobulin heavy chain variable region (IGHV) genes and TP53 disruption.1-3 The acquisition of BTK or PLCg2 gene mutations conferring resistance, supports the existence of clonal evolution also under ibrutinib treat ment.4-8 Whilst it is well described that subclonal TP53 mutations undergo a positive clonal selection following chemoimmunotherapy (CIT),9-11 being the main driver of treatment failure, recent studies have suggested that this might not be the case under ibrutinib.| File | Dimensione | Formato | |
|---|---|---|---|
|
Cafforio_Treatment-with-ibrutinib_2022.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
4.74 MB
Formato
Adobe PDF
|
4.74 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
